Selecting Serotonin Reuptake Inhibitors with Favorable Weight Profiles

Introduction to Weight-Neutral SSRIs

Fluoxetine and sertraline are the best serotonin reuptake inhibitors for patients concerned about weight gain, with fluoxetine showing potential for weight loss in the short term and both demonstrating weight neutrality with long-term use 1, 2
The American College of Gastroenterology recommends considering fluoxetine and sertraline as first-line options for patients with concerns about weight gain 1, 2

Fluoxetine and sertraline have been associated with weight loss during short-term use and weight neutrality with long-term use 1, 2
Paroxetine has been consistently associated with the greatest risk for weight gain among SSRIs 1, 2
Bupropion (not an SSRI but a norepinephrine and dopamine reuptake inhibitor) is the only antidepressant consistently shown to promote weight loss 1, 2

When selecting an SSRI, consider that weight effects vary significantly within the class 1, 2
The choice of agent must be guided by the individual patient's specific type of depression or anxiety disorder 2

For patients with comorbid anxiety disorders, SSRIs are considered first-line pharmacotherapy, according to the American Academy of Child and Adolescent Psychiatry 3

For patients where weight gain is a primary concern, the American College of Gastroenterology recommends fluoxetine as the first choice, especially if short-term weight loss is desired 1, 2
Sertraline is recommended as the second choice if weight neutrality is the goal 1, 2
Bupropion should be considered if an SSRI is not specifically required 2
Paroxetine should be avoided due to its high risk of weight gain among SSRIs 1, 2

The American Academy of Family Physicians recommends fluoxetine as a second choice for treating PTSD, with a starting dose of 10 mg every morning, can be titrated up to 20-80 mg daily, and has activating properties helpful for PTSD-related numbing 4
The American Academy of Family Physicians suggests that bupropion can be considered if SSRIs are not tolerated or ineffective, with a starting dose of 37.5 mg every morning, increasing by 37.5 mg every 3 days to target of 150 mg twice daily, and should not be used in agitated patients or those with seizure disorders 4
The American Academy of Family Physicians notes that mirtazapine promotes sleep, appetite, and weight gain, and should be avoided if weight gain is a concern 4
The American Academy of Family Physicians recommends monitoring side effects, particularly early in treatment, when using antidepressants such as fluoxetine or sertraline 4

The American Academy of Child and Adolescent Psychiatry recommends SSRIs as a class for treating anxiety disorders, including social anxiety, generalized anxiety, separation anxiety, and panic disorders, with moderate to high strength of evidence 5, 6
SSRIs, such as fluoxetine and sertraline, improve primary anxiety symptoms, treatment response, remission rates, and global function, with clinical improvement typically beginning by week 6 and maximal improvement by week 12 or later 5, 6, 7
Fluoxetine and sertraline can address sleep disturbances as part of their anxiolytic effects, though they may cause somnolence or insomnia as side effects in the first few weeks 5, 7
SSRIs generally improve sleep indirectly by treating the underlying anxiety disorder 6

Starting with low doses of fluoxetine and slow up-titration is recommended to minimize initial side effects 5, 7
Monitoring for behavioral activation/agitation is crucial, especially early in treatment, supporting the slow titration approach 7
Close monitoring is required for suicidal thinking and behavior, particularly in the first months of treatment and following dosage adjustments, with a pooled absolute rate of 1% for suicidal ideation in youth treated with antidepressants versus 0.2% with placebo 5, 7

Common side effects of SSRIs include nausea, diarrhea, headache, somnolence, insomnia, dizziness, and changes in appetite, typically resolving with continued treatment 5, 7
If SSRIs prove ineffective or poorly tolerated, alternative treatments should be considered, with bupropion being the only antidepressant consistently shown to promote weight loss, though it may worsen anxiety in some patients 8

Avoid rapid dose escalation, as it increases the risk of behavioral activation and may exceed the optimal therapeutic dose 5, 7
Do not discontinue treatment prematurely, allowing at least 6 weeks for clinically significant improvement and up to 12 weeks for maximal benefit 5, 7
Monitor ferritin levels if restless legs syndrome develops, as levels <45-50 ng/mL indicate a treatable cause 8